<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In low risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:mp ids='MP_0006042'>increased apoptosis</z:mp> of marrow cells is a reproducible finding </plain></SENT>
<SENT sid="1" pm="."><plain>Cytokines may drive this <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Several studies have demonstrated elevated levels of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Soluble <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor (TNFR:Fc) can eliminate biologically active TNF in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>This data provided the rationale for a clinical trial of TNFR:Fc in low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Eligibility was limited to cytopenic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with &lt; 10% marrow blasts </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">Secondary MDS</z:e> was an exclusion </plain></SENT>
<SENT sid="7" pm="."><plain>The study design was to administer 25mg TNFR:Fc twice a week for 10 weeks </plain></SENT>
<SENT sid="8" pm="."><plain>Toxicity did not exceed grade 1 </plain></SENT>
<SENT sid="9" pm="."><plain>No responses were observed in the 10 treated patients and one had disease progression </plain></SENT>
<SENT sid="10" pm="."><plain>At this dosing schedule, TNFR:Fc is unlikely to ameliorate cytopenias in low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>